Introduction
============

Cardiovascular disease (CVD) is regarded as the leading cause of death in Montenegro, accounting for more than half of overall mortality (58.6%). Moreover, an increased prevalence of CVD has been reported in women (52.2%) compared with men (47.8%) ([@r1]). Early detection of cardiovascular risk burden is of paramount importance for better targeting and treatment of individuals that are prone to CVD, as well as for preventing adverse cardiovascular outcomes ([@r2]). In this sense, many algorithms for estimating CVD risk have been validated so far ([@r3], [@r4]).

The first Framingham Risk Score (FRS) included traditional risk factors (i.e. age, gender, total cholesterol level (TC), high-density lipoprotein cholesterol level (HDL-c), systolic blood pressure (SBP), and whether the patient is treated or not for hypertension, diabetes, and smoking) ([@r5]). It estimated the 10-year risk for coronary heart disease (CHD). The updated version excluded diabetes because diabetes type 2 (DM2) was considered a CHD Risk Equivalent, having the same 10-year risk as individuals with prior CHD ([@r6]).

On the other hand, inflammation is regarded to be the underlying mechanism of atherosclerosis, from atheroma formation, progression and destabilization of the plaque until its rupture ([@r4]). Therefore, the quest for biomarkers of inflammation which might add significant contribution to CVD risk assessment has led to validation of another CVD risk score, e.g., Reynolds Risk Score (RRS). Namely, the mentioned score includes parental history of myocardial infarction or stroke ([@r7]), as well as high sensitivity C-reactive protein (hsCRP) as the best validated inflammation biomarker so far ([@r4]).

Indeed, both RRS and FRS predict onset and progression of subclinical atherosclerosis ([@r8]). However, RRS has been shown to improve CVD risk prediction compared to FRS in both females and males ([@r8], [@r9]).

Similarly, many other population-based studies in subjects free of known CVD confirmed the superiority of hsCRP above standard risk factors for risk prediction ([@r10], [@r11]). On the contrary, hsCRP has been reported to contribute little to CVD risk prediction compared to traditional risk factors ([@r2]). In addition, hsCRP was only mildly associated with carotid intima-media thickness in the absence of obesity ([@r12]).

To our knowledge, there are no data on the use of RRS in CVD risk assessment among apparently healthy middle-aged population in Montenegro. Taking into account the high prevalence of CVD and mortality, we aimed to assess the CVD risk as estimated by RRS to examine its association with cardiometabolic parameters in middle-aged otherwise healthy Montenegrin population. In addition, we aimed to test whether obesity had an independent influence on RRS.

Materials and Methods
=====================

Study population
----------------

This cross-sectional study enrolled 132 middle-aged volunteers (mean age 56.2±6.73 years, 69% females). The subjects were recruited in the Primary Health Care Center in Podgorica, Montenegro, during their regular check-up, in a period from March 2013 to October 2013.

The criteria for inclusion in the study were as follows: volunteers without signs and symptoms of acute inflammatory disease, with preserved kidney function (e.g., estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m^2^ and with urinary albumin excretion (UAE) \<30 mg/24 h), and who self-reported to be free of CVD, stroke and DM2. Parental history of myocardial infarction or stroke was obtained from each participant. The methods and assays used to exclude participants and disorders have been described in detail elsewhere ([@r13]).

All the participants provided their written informed consent. The study protocol was approved by the Ethics Committee of Primary Health Care Center in Podgorica, Montenegro, and the research was carried out in compliance with the Declaration of Helsinki.

Anthropometric measurements
---------------------------

Basic anthropometric measurements including body height (cm), body weight (kg) and waist circumference (WC) (cm) were obtained, and body mass index (BMI) was calculated, as described elsewhere ([@r14]). Blood pressure (BP) was measured as previously described ([@r14]).

Reynolds Risk Score is based on age, gender, total cholesterol, HDL-c, smoking status, hsCRP level, family history of heart attack in patient's parents before the age of 60, and SBP. The RRS was calculated for each individual subject in accordance with the score sheet available as on-line calculator at: <https://www.cvdriskchecksecure.com/ReynoldsRiskScore.aspx>.

Thereafter, the cohort of apparently healthy middle-aged population included in this study were divided into low, medium and high risk subgroups (RRS \<5%, 5%≤ RRS \<10%, and RRS ≥10%, respectively) ([@r4]).

Biochemical analyses
--------------------

Biochemical parameters were measured as previously described ([@r13], [@r14]). Blood samples were collected between 7.00 and 9.00 a.m., 12-14 hours after an overnight fast. Serum levels of glucose, creatinine, total cholesterol (TC), HDL-c, low density lipoprotein cholesterol (LDL-c) and triglycerides (TG) were measured using standardized enzymatic procedures, spectrophotometrically (Roche Cobas 400, Mannheim, Germany). UAE was measured with turbidimetric assay (Roche Cobas 400, Mannheim, Germany). HsCRP levels were determined using an immunonephelometric assay (Behring Nephelometer Analyzer, BN II, Marburg, Germany). Insulin was measured by chemiluminescent immunometric assay (Immulite 2000, Siemens, Munich, Germany). Homeostasis assessment of insulin resistance (HOMA-IR) and eGFR were calculated as described in detail elsewhere ([@r14], [@r15]).

Statistical analysis
--------------------

The SPSS statistical package (version 15.0 for Windows, SPSS, Chicago, IL, USA) was used for statistical analysis of the data, which were expressed as mean ± standard deviation or median (interquartile range), or counts and percentages. Differences between groups were examined by Student's t test for normally distributed parameters, Mann-Whitney test for non-normally distributed parameters, or one-way ANOVA, and Kruskal-Wallis non-parametric analysis of variance where appropriate. The χ^2^-test was used to examine differences between categorical data. The relationship between RRS and other variables was evaluated by Pearson's correlation coefficient (r). Multiple linear regression analysis with enter selection procedure was performed to find the independent factors affecting RRS and to estimate the final predictors of its variability. Variables entered in the multiple linear regression model were normally distributed, showed significant parametric correlation with RRS, and showed no multicollinearity. In all analyses, a p value \<0.05 was considered as statistically significant.

Results
=======

[Table 1](#t1){ref-type="table"} shows general clinical and biochemical characteristics of the study participants. Males displayed significantly higher RRS. They also showed significantly higher WC, fasting glucose, TG, TG/HDL-ratio, creatinine and SBP, but lower HDL-c. There was no difference in age, BMI, hsCRP and eGFR between the groups.

###### General characteristics of study participants

      Characteristic                     Women (n=91)            Men (n=41)               p
  ---------------------------------- ----------------------- ------------------------ -------------
      Age (years)                        56.8±6.15               54.9±7.80                0.150
      BMI (kg/m^2^)                      27.0±4.45               27.8±3.96                0.279
      WC (cm)                            90.2±12.82              101±11.6                 \<0.001
      Fasting glucose (mmol/L)           5.40±0.38               5.56±0.41                0.029
      Insulin (µIU//L)^\#^               6.36 (3.60-11.45)       7.60 (3.67-15.52)        0.187
      HOMA-IR^\#^                        1.54 (0.87-2.76)        1.99 (0.92-3.95)         0.180
      TC (mmol/L)                        6.13±1.09               6.10±1.55                0.900
      HDL-cholesterol (mmol/L)^\#^       1.57 (1.32-1.93)        1.19 (0.88-1.37)         \<0.001
      LDL-cholesterol (mmol/L)           4.01±1.16               4.01±1.52                0.989
      TG (mmol/L)^\#^                    1.21 (0.92-1.68)        1.93 (1.13-2.64)         \<0.001
      Non-HDL-c (mmol/L)^\#^             4.29 (3.73-5.19)        4.40 (3.65-5.61)         0.545
      TG/HDL-c ratio^\#^                 0.77 (0.49-1.16)        1.57 (0.92-2.79)         \<0.001
      SBP (mm Hg)                        134±16.7                140±13.8                 0.031
      DBP (mm Hg)                        84.1±11.39              88.2±9.03                0.322
      Creatinine (µmol/L)                58.2±10.19              76.4±11.81               \<0.001
      eGFR (mL/min/1.73 m^2^)            96.8±11.26              95.6±11.01               0.588
      UAE (mg/24 h)^\#^                  6.07 (4.93-8.53)        6.65 (5.05-9.17)         0.521
      hsCRP (mg/L)^\#^                   1.05 (0.51-2.24)        1.46 (0.76-1.78)         0.696
      Family history, n (%)              17 (18.7)               13 (31.7)                0.156
      RRS (%)^\#^                        2.00 (1.00-4.00)        10.00 (5.75-13.00)       \<0.001

Data are presented as mean ± standard deviation or ^\#^median (interquartile range); BMI = body mass index; WC = waist circumference; HOMA-IR = homeostasis model assessment of insulin resistance; TC = total cholesterol; HDL-cholesterol = high density lipoprotein cholesterol; LDL-cholesterol = low density lipoprotein cholesterol; TG = triglycerides; SBP = systolic blood pressure; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; UAE = urinary albumin excretion; hsCRP = high sensitivity C-reactive protein; RRS = Reynolds Risk Score

In the current study, we aimed to test the association of cardiometabolic parameters (e.g., anthropometric indices, lipid parameters, markers of insulin resistance, renal function markers, and blood pressure) with the risk of CVD (as estimated using the RRS). A significantly higher number of males were in the higher RRS subgroup as compared with females (χ^2^=45.9, p\<0.001). Also, a significantly higher number of overweight/obese individuals were in the high-risk subgroup as compared with low-risk subgroup (χ^2^=5.11, p=0.024). Furthermore, we found significant differences in several parameters that are independent of RRS calculation, i.e. significantly higher fasting glucose level (p=0.030), insulin, HOMA-IR and TG (p\<0.001 all), as well as in anthropometric parameters \[e.g., BMI and WC (p=0.004, and p\<0.001, respectively)\] in the high-risk subgroup. Moreover, we found significantly higher creatinine, but lower HDL-c and eGFR in the high-risk subgroup as compared with low and medium risk subgroups (p\<0.001). There were no gender differences in the prevalence of parental history of myocardial infarction or stroke ([Table 2](#t2){ref-type="table"}).

###### Cardiometabolic parameters in subgroups according to cardiovascular risk level

  ----------------------------------------------------------------------------------------------------------------------------------
      Parameter                     Low RRS (\<5%),\                Medium RRS (5-10%),\       High RRS (≥10%),\       p
                                    n=77 (58.3%)                    n=27 (20.5%)               n=28 (21.2%)        
  ----------------------------- ------------------------------- -------------------------- ----------------------- -----------------
      Age (years)                   54.1±5.73^aaa,bbb^              58.9±6.68                  59.7±7.16               \<0.001

      BMI (kg/m^2^)                 26.2±4.46^aa,bb^                28.8±3.70                  28.6±3.68               0.004

      WC (cm)                       88.1±11.85^aaa,bbb^             99.6±11.37                 102.3±12.14             \<0.001

      Glucose (mmol/L)              5.37±0.39^a^                    5.53±0.40                  5.58±0.37               0.030

      Insulin (µIU//L)^\#^          5.00 (3.52-9.25)^aaa,b^         7.90 (4.50-15.65)          10.9(6.40-16.15)        \<0.001

      HOMA-IR^\#^                   1.20 (0.79-2.28)^aaa,b^         1.99 (1.08-3.71)           2.85 (1.51-4.14)        \<0.001

      TC (mmol/L)                   5.92±1.07                       6.42±0.92                  6.37±1.81               0.099

      HDL-c (mmol/L)                1.65±0.45^aaa,b^                1.40±0.45                  1.20±0.38               \<0.001

      LDL-c (mmol/L)                3.80±1.10                       4.30±1.06                  4.31±1.76               0.085

      TG (mmol/L)^\#^               1.07 (0.89-1.36)^aaa,bbb^       1.71 (1.28-2.32)           1.96 (1.21-2.68)        \<0.001

      Non-HDL-c (mmol/L)            4.27±1.08^aa,bb^                5.02±1.08                  5.17±1.80               0.001

      TG/HDL-c ratio^\#^            0.68 (0.47-1.01)^aaa,bbb^       1.40 (0.82-2.09)           1.57 (1.07-2.58)        \<0.001

      SBP (mm Hg)                   129±14.9^aaa,bbb^               140±10.2^a^                149±15.1                \<0.001

      DBP (mm Hg)                   81.1±10.0^aaa,bbb^              88.9±8.1^a^                93.7±9.43               \<0.001

      Creatinine (µmol/L)           59.7±12.50^aaa^                 68.4±12.2^aa^              74.4±12.2               \<0.001

      eGFR (mL/min/1.73 m^2^)       98.7±10.03                      94.3±14.44                 92.1±8.99               0.013

      UAE (mg/24 h)^\#^             5.92 (4.91-7.39)^b^             7.82 (5.11-9.80)           6.96 (4.94-10.28)       0.091

      hsCRP (mg/L)                  0.80 (0.42-1.86)^aaa,b^         1.50 (0.56-2.75)           1.76 (1.43-2.91)        \<0.001

      RRS (%)                       1.79±1.15^aaa,bbb^              6.00±1.14^aaa^             14.21±5.30              \<0.001

      Overweight/obese, n (%)       39 (50)                         20 (74)                    20 (71)                 χ^2^=5.11\
                                                                                                                       0.024

      Normal weight, n (%)          38 (49.4)                       7 (26)                     8 (29)              

      Gender (F/M), n (%)           69/8 (76/19)                    16/11 (18/27)              6/22 (6/54)             χ^2^= 45.9\
                                                                                                                       \<0.001
  ----------------------------------------------------------------------------------------------------------------------------------

^a^p\<0.05; ^aa^p\<0.01; ^aaa^p\<0.001 *vs.* high RRS; ^b^p\<0.05; ^bb^p\<0.01; ^bbb^p\<0.001 *vs.* medium RRS; RRS = Reynolds Risk Score; ^\#^data with non-gaussian distribution are shown as median values (interquartile range); \*p value from one-way ANOVA or Kruskal-Wallis non-parametric analysis of variance, followed by non-parametric Mann-Whitney U test, where appropriate; BMI = body mass index; WC = waist circumference; HOMA-IR = homeostasis model assessment of insulin resistance; TC = total cholesterol; HDL-c = high density lipoprotein cholesterol; LDL-c = low density lipoprotein cholesterol; TG = triglycerides; SBP = systolic blood pressure; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration Equation; UAE = urinary albumin excretion; hsCRP = high sensitivity C-reactive protein; F = female; M = male

Thereafter, we performed Pearson's parametric correlation to examine the potential relationship between RRS and cardiometabolic parameters normally distributed and independent of RRS calculation. RRS correlated positively with anthropometric parameters (BMI and WC), fasting blood glucose, lipid parameters (LDL-c and non-HDL-c), as well as with creatinine concentrations. RRS negatively correlated with the renal function marker (eGFR) ([Table 3](#t3){ref-type="table"}).

###### Pearson's correlation coefficient (r) of Reynolds Risk Score (RRS) with study parameters independent of RRS calculation in all participants

      Variable                       r            p
  ------------------------------ ------------ -------------
      BMI (kg/m^2^)                  0.298        0.001
      WC (cm)                        0.470        \<0.001
      Fasting glucose (mmol/L)       0.282        0.001
      LDL-c (mmol/L)                 0.201        0.021
      Non-HDL-c (mmol/L)             0.313        \<0.001
      DBP (mm Hg)                    0.463        \<0.001
      Creatinine (µmol/L)            0.465        \<0.001
      eGFR (mL/min/1.73 m^2^)        -0.282       0.001

BMI = body mass index; WC = waist circumference; LDL-c = low density lipoprotein cholesterol; non-HDL-c = non-high density lipoprotein cholesterol; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration Equation

Multiple linear regression analysis was performed to explore which of the measured markers had the best association with RRS. All variables found to have a significant predictive value in Pearson's parametric correlation analysis (BMI, WC, glucose, LDL-c, creatinine and DBP) were further analyzed in multiple linear regression analysis for RRS prediction. Non-HDL-c and eGFR were excluded from further analysis due to multicollinearity. With enter selection procedure, the best model consisted of 6 parameters ([Table 4](#t4){ref-type="table"}). These 6 independent variables statistically significantly predicted RRS in the good-fit data model, F (6,125)=15.364, p\<0.001. Namely, WC, LDL-c, DBP and creatinine were independently positively associated with RRS (β=0.305, p=0.019; β=0.194, p=0.006; β=0.286, p=0.001; β=0.267 and p=0.001, respectively). Adjusted R^2^ for the best-fit model was 0.40, which means that 40% of variation in RRS could be explained with this model, for all participants. The parameters of multiple regression analysis, unstandardized coefficient (B), its standard error (SE), standardized coefficient (β), t value and significance (p) are shown in [Table 4](#t4){ref-type="table"}.

###### Multiple regression analysis for the association of study parameters with Reynolds Risk score (RRS)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
                                     Dependent variable RRS; F (6,125)=15.364, p\<0.001\                                                            
                                     R^2^=0.424\                                                                                                    
                                     Adjusted R^2^=0.40                                                                                             
  ------------------------------ --------------------------------------------------------- ------------------------------ ------------ ------------ -----------
      Predictor                      Nonstandardized                                           Standardized coefficient                             

      B                              Standard error                                            β                              t            p        

      BMI (kg/m^2^)                  -0.211                                                    0.153                          -0.163       -1.375       0.172

      WC (cm)                        0.127                                                     0.053                          0.305        -2.380       0.019

      Fasting glucose (mmol/L)       1.722                                                     1.038                          0.122        1.659        0.100

      LDL-c (mmol/L)                 0.847                                                     0.300                          0.194        2.821        0.006

      DBP (mm Hg)                    0.147                                                     0.041                          0.286        3.574        0.001

      Creatinine (µmol/L)            0.109                                                     0.032                          0.267        3.365        0.001
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI = body mass index; WC = waist circumference; LDL-c = low density lipoprotein cholesterol; DBP = diastolic blood pressure

Discussion
==========

In the current study, we assessed cardiovascular risk as determined by RRS in apparently healthy middle-aged population in Montenegro. Our findings revealed that even 41.7% of them had medium or high CVD risk (20.5% and 21.2%, respectively). Moreover, men displayed a significantly higher CVD risk than women, accounting for more than half of males with higher RRS (even 54%), as compared with males with low and intermediate risk (19% and 27%, respectively) ([Table 2](#t2){ref-type="table"}). Our results are in agreement with other studies, which also reported significantly higher CVD risk in males compared to females ([@r16], [@r17]).

Indeed, both the FRS and the RRS stratify a large number of women to the low-risk category (e.g., 76% of women were stratified in the low CVD risk in the current study), raising doubts that they may not accurately define an individual's lifetime risk ([@r3]). However, RRS has been shown to improve CVD risk prediction compared to FRS in both females and males ([@r9]).

In our study, there was no difference in serum hsCRP level between males and females ([Table 1](#t1){ref-type="table"}), although discrepant results have been reported in other, larger studies ([@r18], [@r19]). Cushman *et al*. ([@r20]) in their national study showed that RRS classified the population differently than FRS. Namely, almost 50% of the examined women had increased hsCRP (e.g., \>3 mg/L) and were more likely to have this inflammation biomarker increased despite the much lower FRS. DeFilippis *et al.* ([@r8]) in the Multi-Ethnic Study of Atherosclerosis showed that RRS added additional predictive power for subclinical atherosclerosis incidence and progression, when there was discrepancy between FRS and RRS. Pietka *et al*. ([@r21]) in a cohort of 119 non-diabetic men with stable coronary artery disease and preserved left ventricular systolic function showed that men with higher RRS had lower frequency of marginal or no atherosclerotic coronary arteries.

On the other hand, several studies report that hsCRP has only a minor contribution to CVD risk prediction compared to traditional risk factors ([@r2], [@r22]). In the JUPITER study that included 6760 participants, Blaha *et al.* ([@r12]) report that hsCRP was not associated with subclinical atherosclerosis, using coronary artery calcium and was mildly associated with carotid intima-media thickness in the absence of obesity. On the contrary, obesity was associated with both indicators of subclinical atherosclerosis independently of hsCRP level.

Obesity itself is believed to contribute to low-grade inflammation, as adipose tissue has been found to secrete a great variety of proinflammatory adipocytokines. Moreover, abdominal body fat distribution has more atherogenic properties than overall adiposity ([@r23], [@r24]). It is important to note that although we included in our study only apparently healthy participants free of diabetes and CVD, the majority of them were found to be overweight/obese and were stratified in the intermediate or higher CVD risk group (74% and 71%, respectively) ([Table 2](#t2){ref-type="table"}).

The results obtained in the current study showed that besides traditional cardiometabolic parameters such as high LDL-c, DBP and creatinine, WC was independently associated with RRS ([Table 4](#t4){ref-type="table"}). These findings may support the important link between obesity and CVD, and are in accordance with our previous studies conducted in adolescent girls ([@r25], [@r26]) and postmenopausal women ([@r1], [@r27]). However, the results of the current study extended our previous findings, suggesting that the independent association between obesity and increased CVD risk existed in both genders. Furthermore, since FRS that includes traditional CVD markers may underestimate CVD risk ([@r28]), we assessed RRS, taking into account that inflammation may add significant contribution to the increased CVD risk burden ([@r25], [@r29]).

Other studies report similar results. Su *et al*. ([@r16]) in a study on 882 Malays found WC to correlate strongly with CVD risk in both males and females. In the Filipino-American Women Cardiovascular Study, Ancheta *et al.* ([@r30]) showed that increased WC was associated with increased CVD risk scores, suggesting the need for obesity control as primary prevention of CVD. Indeed, Karam *et al.* ([@r17]) during campaigns for reducing CVD incidence showed that over a 6-year period, several CVD risk factors had decreased, leading to a decrease in the 10-year risk of CVD. Goh *et al.* ([@r31]) in a representative sample of almost 4500 Australian women aged 20-69 years without CVD, diabetes or stroke report that abdominal obesity measures were better predictors of CVD risk compared with overall obesity measures. Similarly, Park *et al.* ([@r32]) report on WC to be a more predictive marker of coronary artery calcification than BMI. Pokharel *et al.* ([@r33]) report on positive association of both BMI and WC with subclinical atherosclerosis.

On the contrary, in a recent study on 610 healthy Iranian adults, Salari *et al.* ([@r34]) report no independent association between obesity indices and atherosclerosis. In addition, results of a cross-sectional study on 120 subjects undergoing coronary angiography showed that anthropometric measurements could not be markers of atherosclerosis in subjects with overweight/obesity ([@r35]).

Despite discrepant results reported from different studies and many novel biomarkers for CVD risk assessment having been investigated so far, it seems that traditional cardiometabolic markers (e.g., LDL-c, DBP, creatinine), and especially obesity indices (e.g., WC) must not be underscored. Thus, strategies for reducing obesity may be of great importance in decreasing CVD risk.

The current study had some limitations. A relatively small number of participants may be a limiting factor when dealing with CVD risk estimation. Therefore, a national-representative sample study should confirm these results. Moreover, since only apparently healthy middle-aged subjects were included, the prevalence of increased CVD risk in Montenegrin population might be even higher. Furthermore, prospective studies are needed to confirm the causal link between increased CVD risk and obesity, and what is more important, to include prediction of cardiovascular events.

Nevertheless, a significantly high prevalence of overweight/obese individuals who were stratified in the intermediate and high CVD risk groups and the independent relationship between RRS and WC observed in the current study may indicate an urgent need for developing strategies to reduce obesity and hence the CVD risk, morbidity and mortality as well.

Conclusion
==========

In the middle-aged study population, in addition to LDL-c, diastolic BP and creatinine, WC was independently positively associated with RRS. In addition, even though many novel biomarkers for CVD risk assessment have been investigated so far, it seems that traditional cardiometabolic markers, especially obesity indices, must not be underscored. Thus, strategies for reducing obesity may be of great importance in decreasing CVD risk in primary prevention setting.
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